EC nod for Daiichi Sankyo's cholesterol lowerers Nilemdo and Nustendi

6 April 2020

Shares of Japanese drugmaker Daiichi Sankyo (TYO: 4568) were up more than 4% at 7,050 yen by close of Tokyo trading today, after its European subsidiary revealed that the European Commission has approved both Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe) for use in adults with primary hypercholesterolemia or mixed dyslipidemia in Europe.

This decision follows on from the data presentations of both treatments at the recent American College of Cardiology’s 69th Annual Scientific Sessions Together with World Congress of Cardiology. Both drugs were approved in the USA in February.

EC key points:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK